

# Lewy Body Dementia Online Course

## Activity Description

This Mayo Clinic and Lewy Body Dementia Association collaboration will provide the learners with a comprehensive understanding of Lewy body dementia diagnosis and management, as well as opportunities to explore the current state of research on Lewy body dementia.

## Target Audience

This course's target audience is medical professionals including, but not limited to neurologists, primary care physicians, nurses, nurse practitioners, psychiatrists, and physician assistants.

## Learning Objectives

Upon conclusion of this activity, participants should be able to:

- Identify three emerging biomarkers for Lewy body disorders
- Recognize the biomarkers biological targets for Lewy body disorders.
- Recognize how these biomarkers can benefit the evaluation of Lewy body disorders.
- Recognize the science related to the emerging use of biomarkers for Lewy body disorders.
- Recognize symptoms of Lewy body dementia to timely diagnosis for Lewy body disorders.
- Identify the medications for pharmacological management of the symptoms of Lewy body disorders.
- Identify two medications severely contraindicated for people with Lewy body disorders.
- Recognize the biological targets of emerging therapies for Lewy body disorders.
- Identify a barrier to Lewy body disorders clinical trial enrollment.
- Recognize the adverse reactions of emerging therapies for people living with Lewy body disorders.

Attendance at this Mayo Clinic course does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course.

## Accreditation Statement



In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## Credit Statement(s)

### AMA

Mayo Clinic College of Medicine and Science designates this enduring material for a maximum of 4.50 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### ANCC

Mayo Clinic College of Medicine and Science designates this activity for a maximum of 4.50 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

### AOA

The American Osteopathic Association designates this program for a maximum of 4.50 AOA Category 2-A credits.

**ACPE**



Mayo Clinic College of Medicine and Science designates this educational activity for a maximum of 4.50 ACPE Knowledge-based contact hours. Participants should claim only the credit commensurate with the extent of their participation in the activity. UAN Number: JA0000238-0000-24-143-H01-P

**AAPA**



Mayo Clinic College of Medicine and Science has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. Approval is valid until 07/01/2027. This activity is designated for 4.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

**ABS**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

**Other Healthcare Professionals**

A record of attendance will be provided to all registrants for requesting credits in accordance with state nursing boards, specialty societies or other professional associations.

**Disclosure Summary**

As a provider accredited by Joint Accreditation for Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities. All who are in a position to control the content are required to disclose all financial relationships with any ineligible company. Faculty will also identify any off-label and/or investigational use of pharmaceuticals or instruments discussed in their content for FDA compliance.

***Listed below are individuals with control of the content of this program who have disclosed...***

***Relevant financial relationship(s) with ineligible companies:***

<b>Name</b>	<b>Nature of Relationship</b>	<b>Company</b>
Jennifer Goldman, M.D.	Consulting:	Curasen, EIP, GE Healthcare, Roche, Sage
	Grant/Research:	Acadia, American Parkinson's disease Association, Lewy body Dementia Association, Michael J. Fox Foundation, Parkinson's Foundation
	Stock:	Neuropath (publicly traded)
	Full/Part-time Employee:	

		Shirley Ryan AbilityLab (through 3/23)
Brad Boeve, M.D.	Consulting:	GE Healthcare
	Grant/Research:	Cognition Therapeutics, EIP Pharma, GE Healthcare
Angela Lunde, M.A.	Honoraria:	Eli Lilly and Company
Kejal Kantarci, M.D.	Honoraria:	Biogen MA (Corporate HQ)
	Consulting:	Prizer Inc. and Janssen Alzheimer Immunotherapy Data Monitoring Board

**All relevant financial relationships listed for these individuals have been mitigated.**

**No relevant financial relationship(s) with ineligible companies:**

**Name**

Dave Irwin, M.D.  
 Jim Leverenz, M.D.  
 Melissa Armstrong, M.D., MSc, FAAN  
 Samantha Holden, M.D.  
 Stuart McCarter, M.D.  
 Tanis Ferman, Ph.D.  
 Timothy Habermann, Pharm.D., BCACP, R.Ph.  
 Kris Johnson, R.N.  
 Katherine Schmidt, P.A.-C., P.A.  
 Corinne Irish  
 Kalene Collins

**References to off-label and/or investigational usage(s) of pharmaceuticals or instruments in their presentation:**

<b>Name</b>	<b>Manufacturer/Provider</b>	<b>Product/Device</b>
Jennifer Goldman, M.D.	n/a	medications for dementia, psychosis, neuropsychiatric symptoms in LBD as only rivastigmine has FDA US approval
Dave Irwin, M.D.	n/a	galantamine, rivastigmine, donepezil, memantine
Jim Leverenz, M.D.	Eisai Lilly	lecanemab, donanemab, anti-depressants, anit-psychotics, sleep medication, cholinesterase inhibitors
Melissa Armstrong, M.D., MSc, FAAN	n/a	discussing many FDA-approved medications but none have been studied specifically in LBD

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) please visit.

## **Disclaimer**

Participation in this Mayo Clinic educational activity does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course. You should be aware that substantive developments in the medical field covered by this recording may have occurred since the date of original release.

## **Prerequisites for Participation**

There are no prerequisites needed prior to participating in this education activity.

## **Method of Participation**

Participation in this activity consists of reviewing the educational material, completing the learner assessment and evaluation.

## **How to Obtain Credit**

To obtain credit, complete the assessment, evaluation and submit.

## **Release and Expiration Dates**

Release Date:	July 16, 2024
Renewal Date:	(If applicable)
Expiration Date:	July 15, 2027

## **Acknowledgement of Commercial Support**

No commercial support was received in the production of this activity.

## **Faculty and Course Director Listing and Credentials**

### Course Director(s)

Brad Boeve, M.D.  
Angela Lunde, M.A.  
Julia Wood, MOT, OTR/L

### Mayo Faculty

Angela Lunde, M.A.  
Brad Boeve, M.D.  
Kejal Kantarci, M.D.  
Stuart McCarter, M.D.  
Tanis Ferman, Ph.D.

### Guest Faculty

Dave Irwin, M.D.  
Jennifer Goldman, M.D.  
Jim Leverenz, M.D.  
Melissa Armstrong, M.D., MSc, FAAN  
Samantha Holden, M.D.

## **Bibliographic Resources**

Liu S, Liu J, Wang XD, et al. Caregiver burden, sleep quality, depression, and anxiety in dementia caregivers: a comparison of frontotemporal lobar degeneration, dementia with Lewy bodies, and Alzheimer's disease. *Int Psychogeriatr.* 2018;30(8):1131-1138.

Spears CC, Besharat A, Monari EH, Martinez-Ramirez D, Almeida L, Armstrong MJ. Causes and outcomes of hospitalization in Lewy body dementia: A retrospective cohort study. *Parkinsonism Relat Disord*. 2019;64:106-111.

McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology*. 2017;89(1):88-100.

Lee G, Cummings J, Decourt B, Leverenz JB, Sabbagh MN. Clinical drug development for dementia with Lewy bodies: past and present. *Expert Opin Investig Drugs*. 2019;28(11):951-965. doi:10.1080/13543784.2019.1681398.

MacDonald S, Shah AS, Tousi B. Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update. *Drugs Aging*. 2022;39(7):505- 522. doi:10.1007/s40266-022-00939-w.

## **Copyright**

Mayo Foundation for Medical Education and Research. All rights reserved. Copyright 2024